Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia

被引:31
|
作者
Kim, Sung-Wan
Kim, Ki-Min
Kim, Jae-Min
Shin, Il-Seon
Shin, Hee-Young
Yang, Su-Jin
Yoon, Jin-Sang
机构
[1] Chonnam Natl Univ, Sch Med, Dept Psychiat, Kwangju 501746, South Korea
[2] Chonnam Natl Univ Hosp, Clin Trial Ctr, Kwangju 501757, South Korea
[3] Chonnam Natl Univ, Sch Med, Dept Obstet & Gynecol, Kwangju 501746, South Korea
来源
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 2007年 / 31卷 / 02期
关键词
antipsychotic; long-acting injectable risperidone; pregnancy; schizophrenia;
D O I
10.1016/j.pnpbp.2006.09.017
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Data on the use of long-acting injectable (LAI) risperidone, the first atypical depot antipsychotic, during pregnancy are limited. A 35-year-old woman with schizophrenia was given LAI risperidone before and throughout her pregnancy. She gave birth to a female infant weighing 2230 g at 36 weeks and 6 days of pregnancy, following premature rupture of the membranes. The baby had no congenital malformation and was healthy 8 months postnatal. To our knowledge, this is the first reported use of LAI risperidone throughout an entire pregnancy. In this paper, we discuss the rationale and problems of LAI risperidone use in pregnancy, based on a literature review. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:543 / 545
页数:3
相关论文
共 50 条
  • [1] Long-acting injectable risperidone for the treatment of schizophrenia
    Moeller, Hans-Juergen
    DRUGS, 2007, 67 (11) : 1541 - 1566
  • [2] Long-acting injectable risperidone
    Ehret, MJ
    Fuller, MA
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (12) : 2122 - 2127
  • [3] Impact of risperidone long-acting injectable on hospitalization and medication use in patients with schizophrenia
    Beauclair, L.
    Lam, A.
    McCormick, J.
    Luong, D.
    Camacho, F.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S263 - S263
  • [4] Impact of risperidone long-acting injectable on hospitalization and medication use in patients with schizophrenia
    Beauclair, L
    Lam, A
    McCormick, J
    Luong, D
    Camacho, F
    VALUE IN HEALTH, 2005, 8 (06) : A202 - A203
  • [5] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Kim, H.
    Hong, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S456
  • [6] Management of schizophrenia - Defining the role of long-acting injectable risperidone
    Curran, Monique P.
    Keating, Gillian M.
    DISEASE MANAGEMENT & HEALTH OUTCOMES, 2006, 14 (02) : 107 - 125
  • [7] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Ciwoniuk, M.
    Godlewska, B. R.
    Olajossy-Hilkesberger, L.
    Olajossy, M.
    Marmurowska-Michalowska, H.
    Limon, J.
    Landowski, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S457
  • [8] Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
    Mohamed, Somaia
    Rosenheck, Robert
    Harpaz-Rotem, Ilan
    Leslie, Douglas
    Sernyak, Michael J.
    PSYCHIATRIC QUARTERLY, 2009, 80 (04) : 241 - 249
  • [9] Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
    Somaia Mohamed
    Robert Rosenheck
    Ilan Harpaz-Rotem
    Douglas Leslie
    Michael J. Sernyak
    Psychiatric Quarterly, 2009, 80 : 241 - 249
  • [10] Efficacy and safety of long-acting injectable risperidone in patients with schizophrenia
    Bouhours, P
    Schreiner, A
    Rendall, MR
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 170 - 171